<SEC-DOCUMENT>0001193125-25-028174.txt : 20250218
<SEC-HEADER>0001193125-25-028174.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218080016
ACCESSION NUMBER:		0001193125-25-028174
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250214
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroPace Inc
		CENTRAL INDEX KEY:			0001528287
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				223550230
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40337
		FILM NUMBER:		25632773

	BUSINESS ADDRESS:	
		STREET 1:		455 N. BERNARDO AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6502372700

	MAIL ADDRESS:	
		STREET 1:		455 N. BERNARDO AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d917599d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:npce="http://neuropace.com/20250214" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2025-02-14_to_2025-02-14">NeuroPace Inc</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-293">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-02-14_to_2025-02-14">0001528287</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="npce-20250214.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-02-14_to_2025-02-14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-14</xbrli:startDate> <xbrli:endDate>2025-02-14</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-304">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt:datemonthdayyearen" id="ixv-305">February 14, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">NEUROPACE, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:stateprovnameen" id="ixv-306">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-307">001-40337</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-308">22-3550230</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-309">455 N. Bernardo Avenue</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-310">Mountain View</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-311">CA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-312">94043</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-313">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-314">237-2700</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration:underline">see</span> General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:boolballotbox" id="ixv-315">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:boolballotbox" id="ixv-316">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:boolballotbox" id="ixv-317">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:boolballotbox" id="ixv-318">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-319">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-320">NPCE</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:exchnameen" id="ixv-321">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:boolballotbox" id="ixv-322">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-02-14_to_2025-02-14" format="ixt-sec:boolballotbox" id="ixv-323">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;14, 2025, NeuroPace, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, as representative of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to the issuance and sale in a public offering of 6,500,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Equity Offering&#8221;). The price to the public in the Equity Offering is $10.00 per share and the discount to the Underwriters is $0.60 per share. The net proceeds to the Company from the Equity Offering are expected to be $60.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses. The closing of the Equity Offering is expected to occur on February&#160;18, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company granted the Underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to 975,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions (the &#8220;Underwriters&#8217; Option&#8221;). The Company expects to use $49.5&#160;million of the net proceeds from the Equity Offering to repurchase 5,270,845 shares from its significant stockholder, KCK Ltd. (&#8220;KCK&#8221;), which represents all shares of the Company&#8217;s common stock held by KCK, at $9.40 per share (the &#8220;Stock Repurchase&#8221;). The Company intends to use the remaining net proceeds from the Equity Offering and the net proceeds from the Underwriters&#8217; Option for general corporate purposes, which may include clinical trial and other research and development expenses, selling, general and administrative expenses, debt reduction and working capital. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act,&#8221;) other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Equity Offering is being made pursuant to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement <span style="white-space:nowrap">No.&#160;333-268243)</span> that was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&#160;22, 2022, and a prospectus supplement thereunder. The foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 and incorporated by reference herein. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the Equity Offering is filed as Exhibit 5.1 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and Private Securities Litigation Reform Act made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;should,&#8221; &#8220;subject to,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this Current Report on Form <span style="white-space:nowrap">8-K</span> include, but are not limited to, statements regarding: the completion of the Equity Offering, the satisfaction of customary closing conditions related to the Equity Offering and Stock Repurchase, and the planned use of the net proceeds from the Equity Offering, including to effect the Stock Repurchase. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Equity Offering and the Stock Repurchases. These and other risks and uncertainties include those described more fully in the section titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in our public filings with the SEC, including our Quarterly Report on <span style="white-space:nowrap">Form&#160;10-Q&#160;for</span> the quarter ended September&#160;30, 2024, filed with the SEC on November&#160;12, 2024, as well as any other reports that we may file with the SEC in the future. Forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> are based on information available to us as of the date hereof. We undertake no obligation to update such information except as required under applicable law. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d917599dex11.htm">Underwriting Agreement, dated February&#160;14, 2025, by and between NeuroPace, Inc. and J.P. Morgan Securities LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d917599dex51.htm">Opinion of Cooley LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d917599dex51.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">NeuroPace, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: February&#160;18, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rebecca Kuhn</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Rebecca Kuhn</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer and Vice President, Finance and Administration</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d917599dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NeuroPace, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6&#044;500&#044;000 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;14, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">several
Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NeuroPace, Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1
hereto (the &#147;Underwriters&#148;), for whom you are acting as representative (the &#147;Representative&#148;), an aggregate of 6&#044;500&#044;000 shares of common stock, par value $0.001 per share, of the Company (the &#147;Underwritten
Shares&#148;) and, at the option of the Underwriters, up to an additional 975&#044;000 shares of common stock of the Company (the &#147;Option Shares&#148;). The Underwritten Shares and the Option Shares are herein referred to as the
&#147;Shares&#148;. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the &#147;Stock&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the &#147;Commission&#148;)
under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268243),</FONT>
including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the
registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means any preliminary
prospectus (including any preliminary prospectus supplement) relating to the offering of the Shares in the form filed with the Commission pursuant to Rule 424(b) under the Securities Act and the prospectus included in the Registration Statement at
the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection
with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities Act (the &#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration
Statement. Any reference in this underwriting agreement (this &#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein
pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any
reference to &#147;amend&#148;, &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date
under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not
defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the
Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated February&nbsp;14,
2025 and each &#147;free-writing prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 6:15 A.M., New York City time, on February&nbsp;14, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this Agreement, and each
Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $9.40 (the &#147;Purchase
Price&#148;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the
Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares
which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section&nbsp;10
hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representative in its sole discretion shall
make. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any time in whole, or
from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representative to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is
being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth
full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the
date and time of delivery specified therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the
Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the
Representative in the case of the Underwritten Shares, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 900 Middlefield Rd., Suite 200, Redwood City, CA 94063 at 10:00 A.M. New York City time on February&nbsp;18, 2025, or at such other time or
place on the same or such other date, not later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the
Representative in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the &#147;Closing Date,&#148; and the time and date for
such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery
to the Representative for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares
duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representative shall otherwise instruct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Representative and the other Underwriters are acting solely in the capacity of an arm&#146;s
length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the
Company or any other person. Additionally, neither the Representative nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall
consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representative nor the other Underwriters shall have
any responsibility or liability to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company with respect thereto. Any review by the Representative and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will
be performed solely for the benefit of the Representative and the other Underwriters and shall not be on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof,
complied in all material respects with the Securities Act, and no Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in
reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in any Preliminary Prospectus, it being understood and agreed that the
only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing
Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representative expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is
required to be included in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other
than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or
referred to and will not prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each
such communication by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus
pursuant to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written
communications approved in writing in advance by the Representative. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433 under the
Securities Act) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the
Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with
respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter
through the Representative expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such
in section 7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Emerging Growth Company</I>. From the time of filing of the Registration Statement with the
Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication undertaken in reliance on Section&nbsp;5(d) of the Securities Act) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;Emerging
Growth Company&#148;). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on either
Section&nbsp;5(d) of, or Rule 163B under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representative (x)&nbsp;with entities that are qualified institutional buyers (&#147;QIBs&#148;) within the
meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#147;IAIs&#148;) and otherwise in compliance with the
requirements of Section&nbsp;5(d) of the Securities Act or (y)&nbsp;with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not
authorized anyone other than the Representative to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means
any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Registration Statement and Prospectus.</I> The Registration Statement
has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the
Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the
Registration Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and will not, as the case may be, contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the
Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in
conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it
being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Incorporated Documents.</I> The documents incorporated by reference in the Registration Statement, the Prospectus and
the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or
the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Financial Statements.</I> The financial statements (including the related notes thereto) of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly
the financial position of the Company as of the dates indicated and the results of its operations and the changes in its cash flow for the periods specified; such financial statements have been prepared in conformity with generally accepted
accounting principles (&#147;GAAP&#148;) in the United States applied on a consistent </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
basis throughout the periods covered thereby, except in the case of unaudited interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT>
adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly, in all material respects, the
information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the
Company and presents fairly in all material respects the information shown thereby; the <I>pro forma</I> financial information and the related notes thereto included or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Prospectus have been prepared in accordance with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and the assumptions underlying such pro forma financial information are reasonable and are set
forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Nasdaq Compliance.</I> The
Company is subject to and in compliance in all material respects with the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act. The Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act and is
listed on Nasdaq, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company
received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. The Company is in compliance with the current listing standards of Nasdaq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options
and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of
the Company, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development involving a prospective material adverse change,
in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company taken as a whole; (ii)&nbsp;the Company has not entered into any transaction or agreement (whether
or not in the ordinary course of business) that is material to the Company taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company taken as a whole; and (iii)&nbsp;the Company has not sustained
any loss or interference with its business that is material to the Company taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any
action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Organization and Good Standing.</I> The Company has been duly
organized and is validly existing and in good standing under the laws of the state of Delaware, is duly qualified to do business and is in good standing in each applicable jurisdiction in which its ownership or lease of property or the conduct of
its business requires such qualification, and has all power and authority necessary to own or hold its properties and to conduct the business in which it is engaged, except where the failure to be so qualified or in good standing or have such power
or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company or on the performance
by the Company of its obligations under the Transaction Documents (as defined below) (a &#147;Material Adverse Effect&#148;). The Company does not own or control, directly or indirectly, any corporation, association or other entity. The Company has
no subsidiaries (as defined under the Securities Act). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Capitalization.</I> The Company has an authorized
capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Capitalization&#148;; all the outstanding shares of capital stock of the Company have been duly and validly
authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except
as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights),
warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind relating to
the issuance of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Stock Options. </I>With respect to the
stock options (the &#147;Stock Options&#148;) granted pursuant to the stock-based compensation plans of the Company (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under
Section&nbsp;422 of the Code so qualifies, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or as otherwise disclosed in the Registration Statement,&nbsp;(ii) each grant of a Stock
Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the &#147;Grant Date&#148;) by all necessary corporate action, including, as applicable, approval by the board of directors
of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered
by each party thereto, (iii)&nbsp;each such grant was </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
made in all material respects in accordance with the terms of the Company Stock Plans, the Exchange Act and all other laws and regulatory rules or requirements applicable at the time of grant,
including, if applicable the rules of the Nasdaq Global Market (the &#147;Nasdaq Market&#148;) and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the
financial statements (including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. The Company has not knowingly granted, and there is
no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its
results of operations or prospects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Due Authorization.</I> The Company has full right, power and authority to
execute and deliver this Agreement and the Other Transaction Document (as defined below) (collectively, the &#147;Transaction Documents&#148;) and to perform its obligations hereunder and thereunder; and all action required to be taken for the due
and proper authorization, execution and delivery by it of this Agreement and each of the Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby has been duly and validly taken. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and,
when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Other Transaction Document.</I> The stock purchase agreement between the Company and KCK Ltd. dated February&nbsp;13,
2025 (the &#147;Other Transaction Document&#148;) has been duly authorized, executed and delivered by the Company and KCK Ltd. and constitutes a valid and legally binding agreement of the Company enforceable against the Company in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&#146; rights generally or by equitable principles relating to enforceability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>Descriptions of the Transaction Documents.</I> The Transaction Documents conform in all material respects to the
description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>No Violation or Default.</I> The Company is not (i)&nbsp;in violation
of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any
property or asset of the Company is subject; or (iii)&nbsp;in violation of any applicable law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses
(ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>No Conflicts. </I>The execution, delivery and performance by the Company of the Transaction Documents, the issuance and
sale of the Shares and the consummation of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of,
or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company pursuant to, any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any property, right or asset of the Company is subject, (ii)&nbsp;result in any violation of the
provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or (iii)&nbsp;result in the violation of any applicable law or statute or any judgment, order, rule or regulation of any
court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate,
have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>No Consents Required.</I> No consent, approval, authorization, order, registration
or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of the Transaction Documents, the issuance and sale of the Shares and the consummation
of the transactions contemplated by the Transaction Documents, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the
Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Legal Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company is or may reasonably be expected to become a party
or to which any property of the Company is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company, could reasonably be expected to have a Material Adverse Effect; to the
knowledge of the Company, no such Actions are threatened by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration
Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Independent Accountants</I>. PricewaterhouseCoopers LLP, who has certified certain financial statements
of the Company and is an independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as
required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Title to Real and Personal Property</I>. The Company has good and marketable title
in fee simple (in the case of real property) to, or has valid rights to lease or otherwise use, all items of real and personal property that are material to the businesses of the Company, in each case free and clear of all liens, encumbrances,
claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company or (ii)&nbsp;could not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect and any real property and buildings held under lease by the Company are held by them under valid, subsisting and enforceable leases (subject to the effects of (A)&nbsp;bankruptcy, insolvency, fraudulent
conveyance, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights or remedies of creditors generally; (B)&nbsp;the application of general principles of equity (including, without limitation,
concepts of materiality, reasonableness, good faith and fair dealing, regardless of whether enforcement is considered in proceedings at law or in equity); and (C)&nbsp;applicable law and public policy with respect to rights to indemnity and
contribution) with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Intellectual Property.</I> Except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect or as otherwise disclosed, the Company owns or has the valid and enforceable right to use all inventions, patents, trademarks, service marks, trade names, domain names, logos and other source indicators, copyrights and
copyrightable works, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, software, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights
(including all registrations and applications for registration of, and all goodwill associated with, any of the foregoing) (collectively, &#147;Intellectual Property&#148;) used or held for use in, or otherwise necessary for, the conduct of its
business as currently conducted and as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The Company&#146;s conduct of its business as currently conducted and as
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and in connection with the development and commercialization of the products described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, to the knowledge of the Company, does not infringe, misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any Intellectual
Property of any person or entity. The Company has not received any notice of any claim, action, suit, investigation, or other proceeding, and there are no claims, actions, suits, or other proceedings pending or, to the knowledge of the Company,
threatened against the Company (i)&nbsp;based upon, or challenging or seeking to deny or restrict, any rights of the Company in any Intellectual Property owned by or licensed to the Company, and the Company is unaware of any facts which would form a
reasonable basis for any such claim, (ii)&nbsp;challenging the ownership, validity, enforceability or scope of any Intellectual Property owned by or licensed to the Company, and the Company is unaware of any facts which would form a reasonable basis
for any such claim, or (iii)&nbsp;alleging that the Company has infringed, misappropriated or otherwise violated any Intellectual Property of any person or entity that, if decided adversely to the Company, individually or in the aggregate, have a
Material Adverse Effect, and the Company is unaware of any facts which would form a reasonable basis for any such claim. To the knowledge of the Company, none of the Intellectual Property owned by or exclusively licensed to the Company has been
infringed, misappropriated or otherwise violated by any person or entity. The Company holds all of its rights under all Intellectual Property owned by the Company, in each case, free and clear of all liens, encumbrances or defects except those that
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.&nbsp;None of the Intellectual Property owned by or exclusively licensed to the Company has been adjudged invalid or unenforceable and, to the
knowledge of the Company, all such Intellectual Property is valid and enforceable. The Company has taken all commercially reasonable steps in accordance with customary industry practice to maintain the confidentiality of all Intellectual Property
owned by the Company, to the extent the value of which to the Company is contingent upon maintaining the confidentiality thereof, and, to the knowledge of the Company, no such Intellectual Property has been disclosed other than pursuant to written
confidentiality agreements. All personnel (including founders and current and former employees, contractors, representatives and agents) involved in the development of any Intellectual Property for or on behalf of the Company have signed written and
enforceable confidentiality and invention assignment agreements with the Company pursuant to which the Company has obtained either (i)&nbsp;sole and exclusive ownership of such Intellectual Property, (ii)&nbsp;unconditional joint ownership or
(iii)&nbsp;a valid and enforceable license to exploit such Intellectual Property sufficient for the conduct of its business as currently conducted. There is no prior art of which the Company is aware that may render any patent owned or licensed by
the Company invalid or any patent application owned or licensed by the Company unpatentable which has not been disclosed to the applicable government patent office. The Company&#146;s granted or issued patents, registered trademarks and registered
copyrights, all to the extent applicable, have been duly maintained and are in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications within the Intellectual Property owned
by or exclusively licensed to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company. The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property of any other person or entity that are required to be set forth in
the Registration Statement, the Pricing Disclosure Package or the Prospectus and that are not described therein in all material respects. To the Company&#146;s knowledge, none of the Intellectual Property used by the Company in its business has been
obtained or is being used by the Company in violation of any contractual obligation binding on the Company, or, to the Company&#146;s knowledge, any of its officers, directors or employees or otherwise in violation of the rights of any persons. No
third party has been granted by the Company rights to the Intellectual Property of the Company, including any rights that, if exercised, could enable such party to develop products competitive to those of the Company as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. The Company is not subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board,
bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any agreement made in settlement of any pending or threatened litigation, which materially restricts or impairs its use of any
Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or
among the Company, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company, on the other, that is required by the Securities Act to be described in each of the Registration Statement and
the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Investment
Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not
be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the
Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Taxes.</I> The Company has paid all
federal, state, local and foreign taxes, except for any tax that is being contested in good faith and for which reserves, to the extent required by GAAP, have been created in the financial statements of the Company, and filed all tax returns
required to be paid or filed through the date hereof; and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or could reasonably be
expected to be, asserted against the Company or any of its respective properties or assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Licenses and
Permits.</I> The Company possesses all applicable licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits, accreditations, clearances, exemptions, approvals and other authorizations issued by, and has made applicable
declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities (each, a &#147;Governmental Authority&#148;) that are necessary for the ownership or lease of its properties
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or the conduct of its business as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, including, without limitation, from the U.S. Food and Drug
Administration (&#147;FDA&#148;) except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received notice of any revocation or modification of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit, clearance or
authorization or has any reason to believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification or
nonrenewal would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>No Labor Disputes.</I> No labor
disturbance by or dispute with employees of the Company exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any
of its or its principal suppliers, contractors or customers, except as would not reasonably be expected to have a Material Adverse Effect. The Company has not received any notice of cancellation or termination with respect to any collective
bargaining agreement to which it is a party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Certain Environmental Matters</I>. (i)&nbsp;The Company (x)&nbsp;is
in material compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements
relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y) has received and are in
compliance with applicable, and have not violated any, (and, with respect to such compliance by and on behalf of the Company by any third party contractors, to the best of the Company&#146;s knowledge) material permits, licenses, certificates or
other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;has not received notice of any actual or potential liability or obligation under or relating to, or any actual or
potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that
would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in each of the Pricing Disclosure Package and the Prospectus, (x)&nbsp;there is no proceeding that is pending
against the Company under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company is
not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of
the Company, and (z)&nbsp;the Company does not anticipate material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Hazardous Materials.</I> There has been no storage, generation, transportation, use, handling, treatment, Release or
threat of Release of Hazardous Materials by, relating to or caused by the Company (or, to the knowledge of the Company, any other entity (including any predecessor) for whose acts or omissions the Company is or could reasonably be expected to be
liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company, in material violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result
in any material liability under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Hazardous Materials&#148; means any
material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos
and asbestos-containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. &#147;Release&#148; means any spilling, leaking, seepage, pumping,
pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into, from or through any building or structure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under common control with the Company within
the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;)) would
have any liability (each, a &#147;Plan&#148;) has been maintained, in all material respects, in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the
Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption;
(iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards
(within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and
no Plan that is a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market
value of the assets of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
each Plan that constitutes a &#147;defined benefit plan&#148; within the meaning of Section&nbsp;3(35) of ERISA (each a &#147;Pension Plan&#148;) exceeds the present value of all benefits accrued
under such Pension Plan (determined based on those assumptions used to fund such Pension Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is
reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, to the knowledge of the Company, whether by action or by failure to act, which would
cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to
the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following
events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company
and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company&#146;s
&#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company&#145;s most recently
completed fiscal year, other than, with respect to clause (ix)(A) and (B)&nbsp;hereof, as a result of a change by the Internal Revenue Service to the mortality tables prescribed under Section&nbsp;430(b)(3) of the Code, except in each case with
respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>Disclosure Controls</I>. The Company maintains an effective system of &#147;disclosure controls and procedures&#148;
(as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in
reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such
information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of its disclosure controls and
procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Accounting
Controls.</I> The Company maintains systems of &#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and
have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP. The Company maintains internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any differences and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the
Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, no material weaknesses in the Company&#146;s internal controls have been identified. To the extent applicable, the Company&#146;s auditors and the Audit Committee of the Board of Directors of the
Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting known to the Company&#146;s management that may have adversely affected or are
reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant
role in the Company&#146;s internal controls over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>Insurance. </I>The Company has insurance
covering its properties, operations, personnel and business, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company ;
and the Company has not (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business as currently conducted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Cybersecurity; Data Protection. </I>The Company&#146;s information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications and databases (collectively, &#147;IT Systems&#148;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company,
as currently conducted and as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and, to the knowledge of the Company, are free and clear of all material bugs, errors, defects, Trojan horses,
time bombs, malware and other corruptants. Except as would not reasonably be expected to have a Material Adverse Effect, (i)&nbsp;the Company has implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
designed to maintain and protect the integrity, redundancy and security of all IT Systems and the confidentiality of all confidential information and data (including all personal, personally identifiable, sensitive or regulated data (including
patient health information)) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
collected, used, stored or otherwise processed in connection with its business (collectively &#147;Data&#148;), and (ii)&nbsp;there have been no breaches, violations, outages or unauthorized
uses, destruction, loss or other compromises of or accesses to any of the IT Systems or Data, nor any incidents under internal review or investigations relating to any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>Privacy</I>. Except as would not reasonably be expected to have a Material Adverse Effect, (i)&nbsp;the Company is and
has been in compliance with all of its internal and external privacy policies; contractual obligations; industry standards by which it is legally bound; applicable state, federal and international laws; applicable statutes, rules and regulations;
applicable judgments and orders of any court, arbitrator, or governmental or regulatory authority; and any other legal obligations, in each case, regarding the security of the IT Systems or the collection, use, transfer, import, export, storage,
protection, disposal, disclosure or other processing by the Company of Data (&#147;Data Security Obligations&#148;); and (ii)&nbsp;the Company has not received any written notification of or complaint from any court or governmental agency, authority
or body regarding, or is aware of any other facts that individually or in the aggregate would reasonably indicate, actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation. There is no pending or, to the
knowledge of the Company, threatened claim, action, suit, investigation or other proceeding by or before any court or governmental agency, authority or body alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> in any material respect with
any Data Security Obligation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>Software</I>. Except as would not reasonably be expected to have a Material Adverse
Effect, (i)&nbsp;any and all use by the Company of software and other materials distributed under a &#147;free,&#148; &#147;open source,&#148; or similar licensing model (including but not limited to the MIT License, Apache License, GNU General
Public License, GNU Lesser General Public License and GNU Affero General Public License) (&#147;Open Source Software&#148;) has been in compliance in all respects with all license terms applicable to such Open Source Software and (ii)&nbsp;the
Company does not use or distribute nor has used or distributed any Open Source Software in any manner that requires or has required (A)&nbsp;the Company to permit reverse engineering of any software code or other technology owned or otherwise
distributed by the Company or (B)&nbsp;any software code or other technology owned or otherwise distributed by the Company to be (1)&nbsp;disclosed or distributed in source code form (2)&nbsp;licensed for the purpose of making derivative works or
(3)&nbsp;redistributed at no charge. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Unlawful Payments.</I> Neither the Company nor any of its directors or
officers, nor, to the knowledge of the Company, any employee, agent, affiliate or other person acting on behalf of the Company has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense
relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any
government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD
Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or
(iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or
benefit. The Company has instituted, maintained and enforced, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company are and have been conducted at all times
in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the
Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no
action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its directors or officers, nor, to the knowledge
of the Company, any employee, agent, affiliate or other person acting on behalf of the Company is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of
Foreign Assets Control of the U.S. Department of the Treasury (&#147;OFAC&#148;) or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the
United Nations Security Council (&#147;UNSC&#148;), the European Union, His Majesty&#146;s Treasury (&#147;HMT&#148;) or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the Company located, organized or resident in a
country or territory that is the subject or target of Sanctions, including, without limitation, the Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba, Iran, North Korea and Syria (each, a &#147;Sanctioned Country&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the
Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such
funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any
person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company has not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with
any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Outbound Investment Security Program.</I> Neither the Company nor
any of its subsidiaries is a &#147;covered foreign person&#148;, as that term is defined in 31 C.F.R. &#167; 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly, in a
&#147;covered activity&#148;, as that term is defined in in 31 C.F.R. &#167; 850.208 (&#147;Covered Activity&#148;). The Company does not have any joint ventures that engages in or plans to engage in any Covered Activity. The Company also does not,
directly or indirectly, hold a board seat on, have a voting or equity interest in, or have any contractual power to&nbsp;direct or cause the direction of the management or policies of any person or persons that engages or plans to engage in any
Covered Activity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>No Broker&#146;s Fees.</I> The Company is not a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against it or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>No Registration Rights</I>. No person has the right to require the Company to register any securities for sale under
the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares that has not been waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>No Stabilization.</I> Without giving effect to any of the activities of the Underwriters, neither the Company nor any
of its affiliates has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by
the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of
Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of
the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has
been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>Statistical and Market Data.</I> Nothing has come to the attention of the
Company that has caused the Company to believe that the statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable
and accurate in all material respects. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>Regulatory Compliance.</I> The Company: (i)&nbsp;has not received
any material regulatory communication that remains unresolved, including in the form of a Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA, or other governmental authority
alleging or asserting material <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the terms of any permits or clearances required by any applicable Health Care Laws (as defined below) (collectively, &#147;Authorizations&#148;); (ii)
possesses all Authorizations and such Authorizations are valid and in full force and effect and the Company is not in violation in any material respect of any term of any such Authorizations; (iii)&nbsp;has not received notice that any governmental
authority has taken or intends to take action to limit, suspend, materially modify or revoke any Authorizations that have not been closed without material impact to the Company&#146;s business and has no knowledge that any such governmental
authority is threatening such action, and, to the Company&#146;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights
of the holder of any Authorization; (iv)&nbsp;(A) has filed, obtained, maintained or submitted applicable reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by applicable Health
Care Laws or Authorizations (&#147;Submissions&#148;), (B) all such Submissions were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission), and (C)&nbsp;the Company is not
aware of any reasonable basis for any material liability with respect to such Submissions; (v)&nbsp;has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any material recall,
market withdrawal or replacement, safety alert, post-sale warning, &#147;dear doctor&#148; letter, or other notice of action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation; and
(vi)&nbsp;has not, and to the Company&#146;s knowledge, the respective officers, employees and authorized agents of the Company have not, made any untrue statement of a material fact or fraudulent statement to any governmental authority or knowingly
failed to disclose a material fact required to be disclosed to any governmental authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <I>Compliance with Health
Care Laws. </I>The Company is currently in compliance with all applicable Health Care Laws, except where the failure to comply would not reasonably be expected to result in a Material Adverse Effect. The Company is, to the Company&#146;s knowledge,
not in violation of any applicable Health Care Laws, and has not received any written notice from any governmental or regulatory authority of potential or actual material <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability of,
the Company under any Health Care Laws. &#147;Health Care Laws&#148; means applicable local, state, federal and foreign administrative healthcare laws, rules and regulations which are applicable to the Company, including but not limited to, such
laws, rules and regulations relating to the provision, administration, marketing or advertising of, and/or billing, coding, reimbursement or payment for, healthcare or healthcare-related products or services, including, but not limited to any laws
related to the development, clearance, approval, distribution, or provision of devices or services. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <I>Clinical Activities. </I>The nonclinical studies and clinical trials
conducted or being conducted by or on behalf of or sponsored by the Company or in which any of its product candidates have participated and, to the Company&#146;s knowledge, the nonclinical studies and clinical trials directed or sponsored by the
Company&#146;s collaborators (collectively, the &#147;Studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement and the Prospectus were and, if still pending, are being conducted with reasonable
care and in all material respects in accordance with the protocols, procedures and controls pursuant to all applicable laws and or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto
required by such applicable laws (collectively, the &#147;Governmental Permits&#148;) and with standard medical and scientific research standards and procedures and applicable Health Care Laws; each description of the results of such Studies is
accurate and complete in all material respects and fairly presents the data derived from such Studies, and the Company has no knowledge of any other nonclinical studies or clinical trials the results of which are inconsistent with, or otherwise call
into question, the results described or referred to in the Registration Statement and the Prospectus; the Company has made all such filings and obtained all such approvals as may be required by the European Medicines Agency, the FDA or any committee
thereof or from any other United States or foreign government agency with jurisdiction over the types of products being developed by the Company; the Company has not received any notice of, or correspondence or other communications from, any
governmental authority requiring or threatening the termination, suspension or modification of any Study; and the Company has operated and currently is in compliance in all material respects with all applicable rules, regulations and policies of all
governmental authorities. There have been no material serious adverse events resulting from any Study related to use of a Company product. To the Company&#146;s knowledge, the manufacturing facilities and operations of its suppliers are operated in
compliance in all material respects with all applicable laws and Governmental Permits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) <I>Description of Health Care
Laws. </I>The statements included in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the caption &#147;Business &#150; Government Regulation&#148; are true and correct in all material respects; and there are no
Health Care Laws which as of this date are material to the businesses of the Company or the Company&#146;s subsidiaries which are not described in the Registration Statement, the Pricing Disclosure Package or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the Company&#146;s
directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including
Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) <I>Status under the Securities
Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2)
under the Securities Act) of the Shares and at the date hereof, the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule
456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or
preferred stock issued or guaranteed by the Company that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified
by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or
other information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is
required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to
10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representative may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, if requested, without charge, (i)&nbsp;to the Representative, three
signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each Underwriter
(A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all
amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representative may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such
period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the
Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements,
Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing
Disclosure Package or the Prospectus, the Company will furnish to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Representative and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve,
refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representative reasonably objects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representative.</I> The Company will advise the Representative promptly, and confirm such advice in
writing (which may be delivered by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the
Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the Prospectus has
been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration
Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness
of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of
the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to
the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or
suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending
any such qualification of the Shares and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery
Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will
immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representative may designate such amendments or
supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the
Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to
the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the
Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the
Underwriters and to such dealers as the Representative may designate such amendments or supplements to the Pricing Disclosure Package as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will
not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of
such jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a
foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject
itself to taxation in any such jurisdiction if it is not otherwise so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earning Statement. </I>The Company
will make generally available to its security holders and the Representative as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder
covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; provided the Company will be deemed to have
furnished such statement to security holders and the Representative to the extent it is filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval system (&#147;EDGAR&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 90 days after the date of the
Prospectus (the &#147;Restricted Period&#148;), the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or
exchangeable for Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any
such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representative, other than
the Shares to be sold hereunder and any shares of Stock of the Company granted under or issued upon the exercise of options granted under Company Stock Plans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described above do not apply to (i)&nbsp;the issuance of shares of Stock or securities convertible into or
exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities, or the exercise of warrants or options (including net or &#147;cashless&#148; exercise) or the settlement of RSUs (including net or
&#147;cashless&#148; settlement), in each case outstanding on the date of this Agreement and described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted
stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#146;s employees,
officers, directors, advisors, or consultants, including contract employees, pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus or pursuant to individual award agreements with the Company described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that the Company shall cause each newly appointed director or executive
officer that is a recipient of such shares of Stock or other securities of the Company to enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters substantially in the form of Exhibit A hereto for the remainder of
the Restricted Period; (iii)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement or inducement
award and described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction; or (iv)&nbsp;the issuance by the Company of shares of Stock
or securities convertible into or exercisable or exchangeable for shares of Stock in an aggregate amount not to exceed 5% of the Company&#146;s Stock outstanding immediately following the issuance of the Underwritten Shares to the Underwriters as
contemplated by this Agreement in connection with mergers, acquisitions or strategic transactions with an unaffiliated third party (including, without limitation, joint ventures, marketing or distribution arrangements, collaboration agreements and
intellectual property license agreements); provided that in the case of this clause (iv), Company shall ensure the recipients of such securities execute and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in substantially the
form of Exhibit A hereto for the remainder of the Restricted Period. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the
sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> Neither the Company nor its affiliates will take, directly or indirectly, any action designed to
or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Company will use its reasonable best efforts to list for quotation the Shares on the Nasdaq
Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Reports.</I> Until the third anniversary of the date hereof, so long as the Company is subject to the
reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, the Company will furnish to the Representative, as soon as commercially reasonable after the date that they are available, copies of all reports or other
communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U>
the Company will be deemed to have furnished such reports and financial statements to the Representative to the extent they are filed on EDGAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each
Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Shelf Renewal</I>. If immediately prior to the third anniversary (the &#147;Renewal Deadline&#148;) of the initial
effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration
statement relating to the Shares, in a form satisfactory to the Representative. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a
new shelf registration statement relating to the Shares, in a form satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The
Company will take all other action necessary or appropriate to permit the issuance and sale of the shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall
include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Emerging Growth Company</I>. The Company will promptly notify the
Representative if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of Shares within the meaning of the Securities Act and (ii)&nbsp;completion of the Restricted Period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not used and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free
writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press
release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference)
in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road
show approved in advance by the Company), or (iii)&nbsp;any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an
&#147;Underwriter Free Writing Prospectus&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not used and will not, without the prior written consent of
the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided</I> that Underwriters may use a term sheet
substantially in the form of Annex C hereto without the consent of the Company; <I>provided further</I> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or
substantially concurrently with, the first use of such term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under
Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing
Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representative. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Representations and Warranties.</I> The representations and
warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates
delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(j) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
reasonable judgment of the Representative makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner
contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officer&#146;s Certificate.</I>
The Representative shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive
officer of the Company who is satisfactory to the Representative (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the
representations set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all
agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs (a)&nbsp;and (c)
above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters; CFO Certificates. </I>(i)&nbsp;On the date of this Agreement and on the Closing Date or the
Additional Closing Date, as the case may be, PricewaterhouseCoopers LLP shall have furnished to the Representative, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Representative, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain
financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the
case may be, shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) On the date of this Agreement and on the Closing Date or the Additional
Closing Date, as the case may be, the Company shall have furnished to the Representative a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain
financial data contained in the Pricing Disclosure Package and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion of Intellectual Property Counsel for the Company.</I> <FONT STYLE="white-space:nowrap">In-house</FONT> counsel
for the Company, shall have furnished to the Representative, at the request of the Company, their written opinions, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance
reasonably satisfactory to the Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement
of Counsel for the Company.</I> Cooley LLP, counsel for the Company, shall have furnished to the Representative, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date
or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representative shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp;
Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representative may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon
such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance and/or Sale.</I> No action shall have been taken and no statute,
rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or
sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representative shall have received on and as of the Closing Date or the Additional Closing Date,
as the case may be, satisfactory evidence of the good standing of the Company in its jurisdiction of organization and its good standing in such other jurisdictions as the Representative may reasonably request, in each case in writing or any standard
form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange
Listing.</I> The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and certain officers and directors of the Company relating to sales and certain other dispositions of shares of Stock
or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents.</I> On or prior to the Closing Date or the Additional Closing Date, as the case may be, the
Company shall have furnished to the Representative such further certificates and documents as the Representative may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter,
its affiliates, employees, agents, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses,
claims, damages and liabilities (including, without limitation, reasonable and documented legal fees of outside counsel and other reasonable and documented expenses incurred in connection with any suit, action or proceeding or any claim asserted, as
such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged
omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the
Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication prepared or authorized by the Company, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any
Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made
in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use therein, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in paragraph (b)&nbsp;below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter agrees, severally and not
jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities (including reasonable and documented legal fees and other expenses reasonably incurred
and documented in connection with any suit, action or proceeding or claim asserted) that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any
information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary
Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any Pricing Disclosure Package (including any Pricing
Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter:
the concession figures appearing in the third paragraph under the caption &#147;Underwriting&#148; and the information contained in the fifteenth, sixteenth, and seventeenth paragraphs under the caption &#147;Underwriting&#148; relating to price
stabilization, short positions and penalty bids (&#147;Underwriter Information&#148;), and the information contained in the eighteenth paragraph under the caption &#147;Underwriting&#148; relating to passive market making. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall promptly notify the person against
whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of
this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall
not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have
notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to
represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and expenses in such proceeding and
shall pay the reasonable and documented fees and expenses of such outside counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of
such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to
retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the
Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the
Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and
that all such reasonable and documented fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be
designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company.
The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or
liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of
counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the
Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written
consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified
Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such
proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an Indemnified Person or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable
by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from
the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the
relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the
Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative
fault of the Company, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution
pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable
considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to the
limitations set forth above, any reasonable and documented legal expenses of outside counsel or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and
(e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount
of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)
of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to
their respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I>
The remedies provided for in this Section&nbsp;7 paragraphs (a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representative, by notice to the Company, if after
the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of
the New York Stock Exchange or the Nasdaq Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or
(iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representative, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the
Pricing Disclosure Package and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the
terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree
to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company
agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless
the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the
Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any
arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of
Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company
shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall
terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that
the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may
have to the Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Payment of Expenses</U><I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement
is terminated, the Company will pay or cause to be paid all reasonable and documented costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization,
issuance, sale, preparation and delivery of the Shares and any taxes payable in that connection, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Shares to the Underwriters
pursuant to this Agreement; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package
and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in
connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representative may designate and the preparation, printing and distribution of a Blue Sky
Memorandum (including the related fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application
fees incurred in connection with any filing with, and clearance of the offering by, FINRA (provided that the aggregate amount payable by the Company pursuant to clauses (iv)&nbsp;and (vii) shall not exceed $25,000 (excluding filing fees)); (viii)
all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors; and (ix)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares for
delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the reasonable and documented fees and expenses of their counsel) incurred by the Underwriters in connection with this Agreement
and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and
their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to
give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such
purchase. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery
of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or
affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where
otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be
closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.
<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to
obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to
properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representative c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT
STYLE="white-space:nowrap">622-8358).</FONT> Notices to the Company shall be given to it at NeuroPace, Inc., 455 No. Bernardo Avenue, Mountain View, CA 94043, Attn: General Counsel, email: lakin@neuropace.com, with a copy (which shall not constitute
notice) to Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington DC 20004, Attn: Jaime L. Chase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This
Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of
venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the
jurisdiction of which Company is subject by a suit upon such judgment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Waiver of Jury Trial.</I> Each of the parties hereto hereby waives any right to trial
by jury in any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Recognition of the U.S. Special Resolution
Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S.
Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution
Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;16(e): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. This Agreement may be delivered via facsimile, electronic mail (including
pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and
be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Amedments or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor
any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">NeuroPace, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joel Becker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Joel Becker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,137,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,137,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,137,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lake Street Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free Writing Prospectuses included in the Pricing Disclosure Package: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Price per Share: $10.00 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">Number of Shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6,500,000 Underwritten Shares plus</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">975,000 Option Shares</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NeuroPace, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term
Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>&#8195;&#8195;&#8195;</U>, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN
SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several
Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the Underwriting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10179 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NeuroPace, Inc. &#151; Public Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as Representative of the several Underwriters, propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with NeuroPace, Inc., a Delaware corporation (the &#147;Company&#148;), providing for the
public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock, par value $0.001 per share, of the Company (the &#147;Securities&#148;).
Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration
of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written
consent of J.P. Morgan Securities LLC (the &#147;Representative&#148;) on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect affiliate to, in each case subject to the exceptions set forth below, during
the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of business 90 days after the date of the final prospectus (the &#147;Public Offering Date&#148;) relating to the Public Offering
(the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock, $0.001 per share par value, of the Company (the &#147;Common Stock&#148;) or any securities convertible into or exercisable or exchangeable for
Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Commission and securities which may be issued upon
exercise of a stock option or warrant) (collectively with the Common Stock, the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or
in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or any
other <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise, (3)&nbsp;make any demand for or exercise any right with respect to the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any
hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument,
however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole
or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise. The undersigned further confirms that it has furnished the Representative with the details of any transaction the undersigned, or any of its affiliates, is a party to
as of the date hereof, which transaction would have been restricted by this Letter Agreement if it had been entered into by the undersigned during the Restricted Period. For the avoidance of doubt, the undersigned hereby waives any and all notice
requirements and rights with respect to the registration of any securities pursuant to any agreement, instrument, understanding or otherwise, including any stockholders or registration rights agreement or similar agreement, to which the undersigned
is a party or under which the undersigned is entitled to any right or benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;transfer the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona fide
estate planning purposes, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by will, other testamentary document or intestacy, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to any member of the undersigned&#146;s immediate family or to any trust or other legal entity for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#147;immediate family&#148;
shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;(1) to a partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned
are the legal and beneficial owner of all of the outstanding equity securities or similar interests; (2)&nbsp;if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, to another corporation,
partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated by the SEC under the Securities Act of 1933, as amended) of the undersigned; or (3)&nbsp;to any investment fund or other
entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a
successor partnership or fund, or any other funds managed by such partnership), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to
whom a disposition or transfer would be permissible under clauses (i)&nbsp;through (iv) above, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) if the undersigned is a corporation,
partnership, limited liability company, trust or other business entity, as part of a distribution to members, shareholders, general and limited partners, managers or equityholders of the undersigned or its affiliates, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce
settlement, divorce decree or separation agreement, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) to the Company from an employee, independent contractor or service provider of
the Company upon death, disability, termination of employment or cessation of services, in each case, of such employee, independent contractor or service provider, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) in connection with a sale of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities after the closing date of
the Public Offering that were acquired (1)&nbsp;from the Underwriters in the Public Offering or (2)&nbsp;in open market transactions after the closing date for the Public Offering, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to
purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise or &#147;net&#148; settlement), including for the payment of exercise price and tax and remittance payments, including estimated
payments, due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the
terms of this Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award
plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of
Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &#147;Change of Control&#148; shall mean the transfer (whether by tender
offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (as defined in Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended
(the &#147;Exchange Act&#148;)), of shares of capital stock if, after such transfer, such person or group of affiliated persons would beneficially own (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) at least
a majority of the outstanding voting securities of the Company (or the surviving entity)); <U>provided</U> that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned&#146;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that (A)&nbsp;in
the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the
Representative a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement, (B)&nbsp;in the case of any transfer or distribution pursuant to clause (a) (i), (ii), (iii), (iv), (v), (vi) and (ix), no filing by any
party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a
filing on a Form 5 made after the expiration of the Restricted Period referenced above, or in the case of clause (a)(i) only, a filing on a Form 4 which shall clearly indicate in the footnotes thereto the nature and conditions of such transfer) and
(C)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(ii), (vii), (viii) and (x), it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under
Section&nbsp;16(a) or Section&nbsp;13 of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally
required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) exercise outstanding options, settle restricted stock units or other equity awards or
exercise warrants pursuant to plans or agreements described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received upon such exercise,
vesting or settlement shall be subject to the terms of this Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) convert outstanding preferred stock, warrants to
acquire preferred stock or convertible securities into shares of Common Stock or warrants to acquire shares of Common Stock; provided that (1)&nbsp;any such shares of Common Stock or warrants received upon such conversion shall be subject to the
terms of this Letter Agreement (2)&nbsp;any filing under Section&nbsp;16 of the Exchange Act made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the filing relates to the
circumstances described in the applicable clause and (3)&nbsp;the undersigned does not otherwise voluntarily effect any other public filings or reports regarding such exercise during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) establish trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares
of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities; <U>provided</U> that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the Restricted Period, (2)&nbsp;the
establishment of such plans is not required to be reported in any public report or filing with the SEC, or otherwise, and (3)&nbsp;no public announcement, report or filing under the Exchange Act, or any public filing, report or announcement, shall
be voluntarily made regarding the establishment or amendment of such plan during the Restricted Period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) sell the Securities to be
sold by the undersigned to the Company as described in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing herein shall prevent the undersigned from (a)&nbsp;sales
or transfers of shares of Common Stock pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act
<FONT STYLE="white-space:nowrap">(&#147;10b-5</FONT> trading plan&#148;) in effect on the date of the Prospectus and disclosed to the Representative prior to the date hereof, provided that any filing under Section&nbsp;16 of the Exchange Act made in
connection with such sales shall clearly indicate in the footnotes thereto that such disposition of shares of Common Stock was pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The
undersigned further acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representative and the
other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representative or any Underwriter is making such a recommendation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (i)&nbsp;the Underwriting Agreement does not become
effective by March&nbsp;31, 2025 (provided, however, that the undersigned agrees that this Letter Agreement shall be automatically extended by three months if the Company provides written notice to the undersigned that the Company is still pursuing
the Public Offering contemplated by the Underwriting Agreement), (ii) the Company, on the one hand, or the Representative, on the other hand, shall advise the other in writing prior to the execution of the Underwriting Agreement that it has
determined not to proceed with the Public Offering, (iii)&nbsp;the Registration Statement is withdrawn prior to the execution of the Underwriting Agreement, or (iv)&nbsp;if the Underwriting Agreement (other than the provisions thereof which survive
termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, then upon the earliest to occur of any of clauses (i)&nbsp;through (iv) above, the undersigned shall automatically, and
without any action on the part of any party, be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in
reliance upon this Letter Agreement. The undersigned further agrees that, to the extent that the terms of this Letter Agreement conflict with or are in any way inconsistent with any prior investor rights agreement, registration rights agreement,
market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreement or any other <FONT STYLE="white-space:nowrap">lock-up</FONT> or similar agreement to which the undersigned and the Company may be a party, this agreement supersedes such prior
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be
governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[<I>NAME OF STOCKHOLDER</I>]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d917599dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g917599g0214220326245.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jaime L. Chase </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 202 728
7096 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jchase@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;18, 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuroPace, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">455 N. Bernardo Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mountain View, CA 94043 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to NeuroPace, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the offering by the Company of
up to 7,475,000 shares (the &#147;<B><I>Shares</I></B>&#148;) of its common stock, par value $0.001 per share (&#147;<B><I>Common Stock</I></B>&#148;), including up to 975,000 shares of Common Stock that may be sold pursuant to the exercise of an
option to purchase additional shares, pursuant to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268243)</FONT> (the &#147;<B><I>Registration
Statement</I></B>&#148;) filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Securities</I></B> <B><I>Act</I></B>&#148;), the prospectus included
in the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;) and the prospectus supplement relating to the Shares dated February 14, 2025 filed with the Commission pursuant to Rule 424(b) under the Securities Act (together with the
Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement,
the Prospectus, the Company&#146;s certificate of incorporation and bylaws, each as currently in effect, and such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable
us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy,
completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the
effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws
are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as provided in
the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters expressly set
forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or
responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the heading &#147;Legal Matters&#148; in the Prospectus and to the filing of this opinion as an exhibit to the
Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;to</FONT> be filed by the Company with the Commission for incorporation by reference into the Registration Statement. In giving such consents, we do not thereby admit that we are
within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 1299 Pennsylvania Avenue, NW Suite 700 Washington, DC 20004-2400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 202 842 7800 f: +1 202 842 7899 cooley.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g917599dsp054.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuroPace, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaime L. Chase</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jaime L. Chase</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 1299
Pennsylvania Avenue, NW Suite 700 Washington, DC 20004-2400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 202 842 7800 f: +1 202 842 7899 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>npce-20250214.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/18/2025 12:21:22 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:npce="http://neuropace.com/20250214"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://neuropace.com/20250214"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="npce-20250214_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="npce-20250214_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>npce-20250214_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/18/2025 12:21:22 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>npce-20250214_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/18/2025 12:21:22 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="npce-20250214.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g917599dsp054.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g917599dsp054.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M,+Y3G)0@YX/<?6E"FH.Z-,7F53&4HPJ+5/<UM5UC3]%M?M.H7*01]!GDL?0
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MSZ\#\C7-3O4J<Q]%CW# 9>L-?5Z?JV2^/[6ZT+QG:>(X8]\3LC9[;T &T_4
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'=!X 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g917599g0214220326245.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g917599g0214220326245.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
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M1SCW./I4>G?%.2.]%OKNF&V4GF2,,"GU4\D?0_A2]M"]KFBR;&N'/R?*ZO\
M<>ET5%;W$-W;1W%O(LL,BAD=3D$&N1\4?$.RT*X:RM(OMEZIPZAL)&?0GN?8
M5<I**NSCH86M7J>SIQN_ZW.SHKRN/XIZM;21OJ&BHL#]U#H3]"V0:]#T77+#
M7[ 7=A+O3.'5AAD/H12C4C+1&V*R[$8:/-4CIW6J/,]:_P"2T6__ %\6_P#Z
M"M>NUY%K7_):+?\ Z^+?_P!!6O2]=URS\/::U]>L=@.U$499V[ 5G3:3DWW.
M[,X2J1PT(*[<$:5%>9+\1/$=\&N--\-M):#HPCDD_P#'A@5T/A3QS:>))6M)
M83:7Z@GRBV0X'7:?4>G\ZM58MV1R5LKQ5&#G*.BWLT[>MCK**XJ3QY+9>,?[
M"U&P2",R[%N!*3D-]QL8Z'C//'/I7:U49*6QRU\-5H<KJ+XE=>@45Q=MXZEU
M'QBVAV%@DL*2%6N#*1A5^\V,>N0.>>/6BB,E+8*^&J4&E45FU?Y'$^"IDT7X
MBR6UX=C,TMMENSYX_,C'XU[57GGC[P//J4YUC24S=@#SH0<&3'1E_P!KV[X]
M>N1I/Q1O]-C^QZU8M<2Q':9,^7(,=F!')_*L(2]DW&1[N+P\LSC'$X;625I1
MZH]:KB_BA>RVGA'RXB5^TSK"Y']W!8C_ ,=%8%Y\5KN[_P!&T?22)Y.$9V,C
M9]D Z_C72W&A7GB+X?PV.H,Z:D8Q+NEZB0$D9],YQ[9JW-3343DI8*>!K4ZV
M*22YEI?7U]$)\.=(M+'PM;7D<:FYNP7DEQSC) 7/H,=/7-6_'&D6NI^%KYYT
M3S;:%IHI".5*C.,^AQBN"\/^,-0\$AM%UG3Y6BC8L@SATR><=F7J?ZU+X@\>
M77BFW_L;1-/G7[1P^>7<>@ Z#U/I4*I#V?*=D\OQDL=[=/W;WYKZ6_X8T/A[
MJUQ!X&UDY+?8%DEASV^0MC\P3^-5/A5I=O>WE_JMTJS7$+*(R_)4MDEOKQU^
MM=CX1\+C1/##6%V%>:ZW-<@'(^88V_@/US7 0G5_AEK\S-;M<:;.=N[HLJCD
M'/9QSP??ZTK./*Y;(TC4AB98FEAW:4FK=+I;V]=?O/7KNSM[^UDM;J%)H9!A
MD<9!KRGP$7TCXA7^DQ2,UN3+"<GKL8[6/OP?S-:&H?%J-[-DTW3I1=.,*TQ&
MU3ZX'7]*L_#GPO>V<\^N:JCI<3J5B23[^"<LS>A/^-4Y*<UR]#GHT*N"P=;Z
MSHI*R7=]_D8VM?\ ):+?_KXM_P#T%:7XI74L_B?3[!4>:..%6$*Y^=F8C QW
M( %)K7_):+?_ *^+?_T%:WOB/X:N[XVVM:8CR75J KH@RQ4'(8#N0<\>_M4-
M-QE;N=U.K3IU\*YZ?N[+UL58O&?BF"%(HO!LZ1HH556WE  '0#BL"0^(+[QE
M9ZVOAR]LI%E3S?+MI,-SAB<CNIP:W].^+5F+15U.PN1=*,,8 I5CZX)&/IS5
MSPQXPUOQ+XAD,&G(FC@89FSE/^!=V/I_^NG[LK+FN9*-;#*<_J\8V3N^9Z_C
MK<B^*>@_:M-BUF!?WUK\DN.IC)X/X'^9H7QT#\-FOS+_ ,3)1]DZ\^;CA_\
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MY>6^@4R6&*>)HYHTDC;JKJ"#^!I]%,E.VJ*%OHFDVDHEMM+LH)!T>*W12/Q
MJ_110DD5*<IN\G<A:TMFG\YK>(R@YWE!N_.IJ**!-M[E"?0](NIC-<:7932G
MJ\ENC,?Q(JY'%'#&L<4:QQJ,*JC 'X4^BE9#<Y25FS*\2:RF@Z#=:@V"\:XC
M4_Q.>%'Y_IFN)^%FCNXN_$%UEI)F,43-U/.7;\3Q^!KL/$?ABT\3P007ES=1
MQ0L7"0,H#'IDY4].?S-:6G6$&EZ=;V-L"(8$"+GJ<=S[GK6;7-4N^AZ<:L:&
1 <8_%4>K\ET+-%%%:GE'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46653227114192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroPace Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001528287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 14,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-3550230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 N. Bernardo Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mountain View<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">237-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NPCE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  '0%):8D^Y#60$   G$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V886_J-A2&_XJ53=,FM4UBH- .D"AMM^K><EGI=J5-^V"2 UA-XLQQ@/[[
M'2<T8;OAA"\0AYPWC\^Q7]L,=TJ_91L P_9QE&0C9V-,>NNZ6;"!6&17*H4$
M?UDI'0N#3;UVLU2#"(N@.'*YYUV[L9"),QX6]^9Z/%2YB60"<\VR/(Z%?K^#
M2.U&CN]\W'B1ZXVQ-]SQ,!5K6(#Y/9UK;+F52BAC2#*I$J9A-7(F_NT=[]F
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ !T!26APX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    (  = 4EHD'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !T!26F^(_*_O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M!T!26IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  '0%):8D^Y#60$   G$0  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M!T!26I^@&_"Q @  X@P   T              ( !J P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  '0%):EXJ[',     3 @  "P              @ &$
M#P  7W)E;',O+G)E;'-02P$"% ,4    "  '0%):'#AEZC\!   \ @  #P
M            @ %M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ !T!2
M6B0>FZ*M    ^ $  !H              ( !V1$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ !T!26F60>9(9 0  SP,  !,
M         ( !OA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  "!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d917599d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d917599d8k.htm">d917599d8k.htm</File>
    <File>npce-20250214.xsd</File>
    <File>npce-20250214_lab.xml</File>
    <File>npce-20250214_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d917599d8k.htm": {
   "nsprefix": "npce",
   "nsuri": "http://neuropace.com/20250214",
   "dts": {
    "inline": {
     "local": [
      "d917599d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "npce-20250214.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "npce-20250214_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "npce-20250214_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-02-14_to_2025-02-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d917599d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-02-14_to_2025-02-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d917599d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://neuropace.com//20250214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-25-028174-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-028174-xbrl.zip
M4$L#!!0    (  = 4EH$'7J-LQ4  'E^   .    9#DQ-S4Y.60X:RYH=&WM
M/6USXD;2W_TKIDARL:MXD038!GNY<E@VX787^[!S2=V7U" -1L\*29F1##R_
M_KIG1D("9+"-[=W$J<H:-&\]_=X]/>+\G_.I1^X8%V[@O_O1K!H_$N;;@>/Z
MM^]^O+CN]OL__K-S<#Z)H!MT]47;8>Z[TB2*PG:M-A]QKRJ87;T-[FK04+,,
MJU'2'6-1B18A$VGO,16C:L!O:TE+KKL?^'X\33O/9K.JG!X'.!&OX8@:=*I
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MODR;HE<G%A@,D'V :&E5\L;M:RGP+,P=*,.X,*V1U!!/.']IE3KHZ@%*KJ/
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M'[&Q&\X2C;&Y=S%!97APJ\O;DFMUR%3P">0SP=:4+G2=*TJKBP=6'L0:,EY
MN99V%/%)89_RD0.&P M":7D2:0?1!%<&P"VG2V)7ZDQA1@QRI"59]G;8"&M
M'55Q)_O. OY%BBP-W8AZU7O>=K"?X.TFB[Z<M921"A!)9#1*UBB"5 'Z*$>]
M@893;C49+)"#,JQ6SJJE5!TA1V@E)>-$-O67=[Z6M9"K?)MR0Y;NV4)E)+KG
MTI'K*9M>6!FF,R'2X-.I"C%S_)WK7DX=",40&R $XYHB Z "PJO-+ LTE6AL
M0Z0=@--&?:D3)1548B<JIM8,O _@!F#@P/<6$@4)ER-P(D;&37M+8JD&];X*
MF^"[6! 0G ?B):8GP25'P,UC-UK=)):TKD^+L@3F-6.E/'?JZHVJO@X8!$ *
ML(@<K^=[&6;?8'U'3)5@.2P7_V_2E$FZ0A)5O@I [ANM]4XUPM>5>F(F#X?9
MN:[3N;;.,0BJROK4Z_6*=7QJ->KI\7@T 8T]D]E VZ/H-3/8J'1&$XG,\#22
M*TUH+._?YD6@UUVR/=[$O&-X+T!!8%G2*8%_)4,AFR,_13%8KS@,/;4CZ1E+
M&53,C['R;2#M-1,V=\-LP3-*32I.!;P.-/LSAD G^YH5O"_*&5!VA&I*OQQS
MS;',S9-H?YAN['I,2D1O/G%'P.IFU91[<M/+V,S)3ZW<_2JY !$-TYKL( 1=
MKW;3#4"*%A!07*WY^!Z[!?"C=-2ZSY_$&\IN%_O6:X W 7 $+0KNE:?39[BG
M4>J $( B<\BG()!F+.5J<0\L>XDU;S EW(TY1_[0[[K:62HSE?NIT1NKK50\
MO16QW J&CYHB4T9][=KK=*$6C).+@N0[4CC?U>SMF#//FBDE<5?<O4-_)AN_
MPA]]A6"(6:FIG&&C<A-T#&Q,^0AMQ?(&@09FY[DE=*VFE&W!LHC2IB!]#:R4
M('!Q'*$-ATBT#)H^O'47L<3()BTCYKG@:ZT^UC[YZF/M:JX^!D!6'X4>]5>?
MB4D0>\[:T]22K;;,P/U?>X93),^01G<4;Y5D, LX4C@ M LPC:"GT2G$BT+*
M*4(=CIYV]NZ(QN'B'KX$EO BV,'M1*;/T>V_AXDUHV<!JI(/Q?UEU_W(F/:T
MRV04JXTBN-))D'LM9Y<%2P$  2QMR90RT\^R]F)%)Y8?'!,KY:RP7!1ZK,8Y
MY=0%139"YPP#FX=$@5EW%1965EHI@96U@"JPD8!KQK"1OR ^P 7A.9A!#$QB
M3\6GCHOSI^7D7B8E<@\O;"4(=\47Y2[$8*4X,HYR((0(;%=B3^;4INIH-8/<
M!$_[IL@F3(E$!65BM@+ DV /Y 7Z*S=D!"M.P34AXQ@1IS6\T*= \OWT3B+E
M0Y@WH4M6V'7S9^K3VS3G*#W']ZZ /8LDT+OPJ;<0KM0)']+#J6Z" ]EGJ.D*
M72XA_E9*)+L:\P2;H;%'8(.8)\D2=9M,&2J%J5XWRW#8]=^Q?"T=;'0IR5N%
M&$5=IZ.,RK_5)^"KI??)T#'#>8G27-<LC#+^8MV0_B)8,N6W9 %<]RY-*^D-
MAF(&H;6T?WC_3<?C"+<6BQF3U@:GS<^JR3B.HQ@SB/=HN)5(:S^Z#J4)7]SN
MX&C73W^/@= ["IH?3UQD6D1'8S(KBE87J1J,J^0WG>&*Z!<4R^P-01P7RL[2
MF&8G9W,;$*_2V" \& ?HVX/IE5GBT5E5'U1E#L$.R,';.=C;.=C*.5CKVSX'
M6RK83$"B@E\9-.UR./:"A=;[X;D=*JT/#E2MM?SCU/3?7:JC3PJJHUO&BU5'
M[ZGT>2=VW*%LE20_,Z-^@J<R\L YV7N!IV98Q5N#H/J(HMR]E^9NLH O5@6+
MK]Q,<TAY(=;<O4& UW@I>0T"--0*6\!!0.GUWY6LUWQ?ZL8"O*JY)RY87Q#L
M!"7J!VR<EGG2;+4<-C?-ZB2"R8H2:X[TWXM._T<JA3]BT8PQ?ZT8 -N*3^=1
M5].BDN:_,I&;+TWDIB;RY::<YM^6#%;]M>@ T:&0IPVYW/*ACF5EV)*S#\ P
M1W];,IE&XQFIU(5 E9,KV!ZH++#,5!VQO*<1)?+MH8<8QSJ.CG%U$-J7K@'!
MG^<CCOXQA:.,P4K=SK>0+!N2O>KK(*_[/P\N;GX=]JZ?_7CR:B4_KV-W%:X\
MYH@ !PSS!=9.["U4]M!1.0Z51=$U45ARHE,5>(3/)M0;)^>&,H&@.Z@#/<PW
MXG1 ITG 89/.VI'37R%J6HV3\JS=:&+$LWOD5/@FUAVG*;B5NB<@FFGXMN(]
MO]@+87>[X?NPUVD^RYQ+VU??FDI9\7#O?TOF#E89A:G +,NFO%W>;[=7?%FP
M^C4CIUU0&OD\[V+=+_-([^&G1?N98'U@X+WEIL0#[5=-U,#<C)AM4_(QGOBO
M>_7T&U,GSS%G)T^--TJ\'B6Z$Y=E3_HNY2N%N<QU_ >+Z:\X$_*0OZQ[J6/,
MBTSQ:.#O$BN<U]0O8,L?Q^[\#U!+ P04    "  '0%):Q+YHCLFD  "R*P,
M$    &0Y,3<U.3ED97@Q,2YH=&WLO>MRV]:6+OJ?57P'5'KO+JD*=B1?<E,Z
M58KM9'FWD_C83F?W^0>2H(28!+@ 4#+7TY]QG7/,"8"D9-WZE'?U7K$D$IC7
M<?W&-W[\QX??WOSTXS]>G;[\:3SZ\</K#V]>_?3J_SXZ?GS\X]?\$_SZ:_E[
M\N//?[S\[^3G7U_\\>:/=__QU5__>/WAU5?)^P___>;5?WRU*,K\T7E>G)VW
M/_Q>U<ML\=5/R7@$WW^1EVU>__3CR]?_I1^^+&;M^0_?/7Y>E%\EV:(X*^$!
M^;S]BE[S5C^VS.JSHGS45JL?CE;M22(_3ZJVK9;\JWE5MH^:XE_Y#\?^YWFV
M+!:;'SX4R[Q)?L\ODW?5,H,WG;YY_>OO__%5C8/\ZJ<??_[IU:?S8E*T"4PX
M^?'KGW_Z\>NW...^ 1P_N<$13&E)OOKI]WQ=5V^S:9XFK\OIX^2NW__-O__;
MT;-G)\^/CO@?1T='R?OSK(8O5?/D1;5<5F7ROJVF'^]\:'^6L[R^K(NV*,^2
MT[,ZSY?PESL;AIR17_))O<[JS;^7DV9U<OPL39X</7E.H^@_IS<RB)_^S^.W
MCY/?JOHL@^7/IVM<AKP9C]Z\>;'EW3=Q1WXZ;9)W^0I. *QVUA87.9Z$]CR_
MQGOE5WBQ?WCROZ\XCB:_R.ML,1ZY@Y#73;(HFC:?W?58"MB%Z7D^6R_RY#@Y
MS^N\K6[])/XT_;I*^@]"<@?GX.EW3Y/?LEG1@ 0XO<C+=;YMQC?R2OSG?U?U
MQS31?R7'1\???G_KU^T-S!-^DY6SY%<X]@L4-3]LF^XW V]M\T_MHP(.;-G^
M\.RJIRQ2!FF2)2_S178)XCB95O6JJN$^PFX<X&W\]W\[?O;M"4CH559N\(?O
M3@[39%57JZJ!Q\+Y+)H&]@SGU.2+!?X&OR?7*EGWW*K@F(]'<L[-Z^Q5=.^<
M5W5R>5XMDTVU3G"LV91D=M8D=2A(S)-"$>.>!:<\.P-9?Y:U)'?Z]%/C]-.4
M]5.#^@GFGM7)1;: .?^OH\='1\?)*J_YPZF*,%FNWBFU>3D>L>Z3X>#:P9!:
M^FJUHK67!]F%2)/U"E<7QSZ;%?@Q6-_OOWV^:\A;1O4'ORT8SN/D@WTSC%=5
M->XQ?C?X%FT%;B'L:IW/\[J&'<9A-OC9\8A?9-_ +]AOK/"@"2S*NFU:>#MM
M]QP6(SDK+O"'?#[/IZT[<]G":1$S.#LJ&2@/3A:![ X=VG6D[6?=Q@]FMCBZ
MR086I)P7];))BA9FX$R2RZ(]#^Y6H+'@2].\+G%5\#.K=3T]SQJYF)V%27$)
MYM5B45TV6R70[4SZ&!;ZSY_>Y6<@$$3:O(<K2O/\\>L_?^(CXI8%Q@K7&"X>
M;"+.9UXLX%]N/8S"PK^^^@0S+\_H^TN03EU9)K^5 S\>D9"*'W4*!PO6[/C[
MIT]IM3(8W"S'FRK7H ;YQ6\$0;)>T#0:<X#UW2UN*[_B8 I+#B<69-%BD]HS
M&+S7RRE\M%^C1M<H.?@%EB#Y\9<_?O_@?)US. B/FA4(]A_*ZK+.5B#JJ\=L
M43Y]^O31DV^^>_+LZ6'ZX]?X-=CPHIPNUGRI4*(W*QC9&HY&G>-D\"!5YL@\
M3MZOI^<# [(KI**LA5V'(PP7> I_D;L*,T\3_V+\7%'.T8_#!\*?YK"BL#0S
M//0S/,;-.BOIBK]#??'LZ=%IBO_[<P+Z /[[(AG</18><&Q:V97Q:& Y[8CA
MHWCOW'#+O&F2 U$G,@10G&[,;K.*9J>HZ3_Q_(03.DKP\74##^!O\Q&!^[V4
M![R%O2F610FN0O+6;1D_(%GF68D'<H.W13\V'OFM30[,EH<?,P<@:=:K%=DF
M[6'G+%2P+#7^',K9@HXYZNAE?#O-3>CNYI-G!Y/#X1W4JV8&QS-@*P+_U+^D
ML*/CT?8M;<]AUZLE_J%O6_T]#Y:_=\D[0[2+43<M;^D!'-AE-@.1?)$5BVP"
M[URO*M2:_USG#9U1E=H@SSMK=?SMT\&%.L1W@@8H<7X5&!BT^J)',K4H4 TT
MX<8]3EZ'"A=E+6\@VAF329U?%!D:;0,WI[NEWSP)MU24R]<O7__73S]^+4&:
M\2BA__MQ!<_:+/)0Y^3+CLK!7ZVRL_P1C"C[^&B2P^KF/V2+RVS3? 5&^]<K
M?,D_WB7O7_^_( R??J7/I2#2#__V/?V_KY*_7K_\\(__^.KXZ.A_.Q_\Q:O?
M/[QZ]^#"2/#PZ#I8PU;6>N#\.Z$$WRCIKI-HRL%&4,$D%]J<[FV/0GL-K'N0
MIR*9T?+GJPCR O1"[X!@!OJ8Q\EI, JZ)" RUS;^XHV= _HCC\M%9=1@EJ'W
MCS>EZ?8+2M09^$WSFYYYT2#9U)ZY2>+79M5TC:\@*22>$GQE8N?5\O*"V#4W
MXS4,+3E^@G?O%Y0*.Q7W^T=/14T/WGE2N7*9G61+9N+1;!&-L@;Z2=J]?9<K
M57TV1=MRF6U@Y5A2PJ*C>G7+4,GFD5' &Y?:7YFC!6_A/WC%(W\A,09B:F6L
M_#O==7RHWW41C.2!T++A&@Z8C\X*]7;DL]NW(^U;W6U!18>.D)_K)-]]@A\G
M+[)5T8*X^Q=^*4>'A/389-TF907Z=9;/B]+9*K*FY]D%7Q94C7"G&_35<A(W
MM&3\H!W*6U;&;]CCZ\1F/LM%.:6+LJJ+JI:3-QZ=PO$LIJ2Y\?/) 6RG+L(D
M!U^*!:Y1IC/ON+!)@!X72CIC](:[Z0TG>/<T_FB3MVA7P"<P7 ;Z_E-R:O?_
MK7SG9=%,%U6SAEU_FTT_@N*4T_ #V/H#MV1&1Z$3B1Z/*!2->Y)GL('\HCF(
MY$<JME>Q6607IFLA'#W?8LA(C,A/3^*@]^":B_8)-STP_+[YX?AY<OKXM\<F
ME/BB:#=D=J8XB?[ _CU,Y@FYW&\U+!!8@>QRW_F0#K+#P,\G[=\;4QP(2$6Q
MQB >0C&#ZJ)PK@*8$\Z02-UQ#N+^M&/XQ$G6%$X$V^@B2.8TN<SJ&@ZTQAN<
MT=*8ZZG>'TYA/?G;Z"^PRCEZU_UX*DN0ZI1 '. 30-HF?U=%V9*PKTQPIR77
MO0"I[:*0..S_]?WC9T?67-1]'X]00J@P2.9UM0SC;31?NLQH393KY02>"T_L
M6WXCC%:KJH$59!%O5A1?],U)DY08 >A+;]S#L7OM ZBAN-YZ_L*@YV>>/-(F
M87#WOD]>I+TE#FT.V]9#V7N0HCAQR]-V(HA.8K) 7QQ]S66U1G_2'6/PBK,%
MVV-@@Q6XGN6,;+D9V@P%F"$TE5D^79""G6S"W80QKK(-"6Y9W+Y#+-9,_-%@
M[/=Q2"D.UA-JEZ"6+.*,3["_IYUC:C^,2T0ZW!P];PIO>=!X!$X*?&^29W4C
ML7:XT&2XZ>GR"96AT4QR,A;<:,25N+*0H2]E2^^]V.GTYE Q]$*?E'>!\5OG
M.@;_AH*2GQ348W5]Q-FI:GZH4Q^>:^_ABF;<N29R9OOD2*K7-TW.JTO\0.J,
MZ&SV][II^>;#[\2<:]E?F=?95+)#>FX:L;:#-!G,%H-?304K!5<*5H1-3#P/
MX]$R^Y@__A*\N=$\3Z FT'G./^7UM&B&1&Y7@I)H+5B77I[#SH'BJ,<C/E?X
M>SR@\G<,?)->@<//2\X!G_.B!@W2HO>Z,1Z)C0G$3C\<4SW9("M1;+N3'!TJ
MN2!ROB5G(-]A2>.OVWY2(Z,CSO+'+%,!0HFOER[BS/F-,[X*,UZ*2PR!]><M
M63[.X/[ ]9('K+)BA@-,Y9T<Y/!"+WRX7*T7X&R1WX5_1.^'U2J'"L03.B1=
MPXN &@<>"C)E49 CE)7=YY2P<8NLM7^''6C!9IVO462OX:.H/7$?!]_)/W8"
M/K(E!^N2%#"[YC0AF!E/$=8'!&Z[JDHV9++IM*IG&88(C(\*ADZC 8M(>"8B
M.SGTUW1. BP QP;@8"] '(.!<%D%TVHB!SQ<>WBC;!T\'8YJ,2_8S^;PQ5U'
M###L;=T9\G$I;RW)AC86 6 \Y24%9%#:HBF_GH"O&2=9%"^02F@*;#BRPN![
M]$F;B*GTG&"4)=!L?*>'P@-AQA5^5U:7BWQV9BW-H6G@#>&!.(O9VQ\4>ZNK
M]=DY":]L/B\6A9Q$.-3F0??A@4X/80$V%'2:5\%"NB-**1L4@ 4*##"_FSF;
M&<5RF<]P*F@0NY3.?$W[+78"7!FT:OWIC(Q4/=A=U>R"K#$4Q)L7'C0"BSKE
MU,[+#.YC\K9:?.1;^._9<G62_)75LTO<ES=OWJ;)]T='R6_%; 9:L,@7L^3=
M['$*@AI-JR='1RF(]-EE5<THDI$F+TZ3[Y\=??,47W9\] -\%P,>/?&.GG#'
M=QSN0"6%7R<14.$%E2^ ZEHMLJFSNDG JJW&'\0KGY*\C$3AO)C#P0Z$(%U]
M$GCI@,VC&D+7'X\NG6U.Q:%6E9@6*H">;0ATB//:G%RRB612)C2[>/N']CO2
ML3T@(/:GP>!C21L8"[1HD=_RP0XF4 "KZ-CWF:][9+2MPDHE-N82I\&+Y[C;
MO:^.UK28ZQGITXJ49Q_$&VG&R .D['<?RP#O7,X,R)C8/:MZC #YQL",^O,Q
MH>S*SK*B!.6JNG(\<IF4X!#JX$S\1^27"TCTQCM")$#/G%RJY%J3(5N#9*7*
MWC;[!"]2ASW(?!N0E&">Z.7JQ8)7N&$#+Y3#CQ$!R89$.)MP)561D?C)IJ#(
M*!0#7\%[]C(G_[2"AWRHP3WS@#L^E"\_O-"XFUA=/9O +Z3S?XF. >Y<O9ZV
M]Z$<9X=7,PH&9"U?YC!$YN&;Z'["ICA1NX)U;3=B'63U4B*(X]$B+\\8U-"B
M@XO!(3J<>8V.SB;R/'I3A]:ND@W&Q^7+U8)R'X*_,RB9GL,UR]&X*AS2CDTM
M.3;ZAD,7(L.,'^BJ$NQFL-K <P?]#-< %2+\>K:&W]8X>-:1B$NE'.T\946A
MTZ$_;F0M5["&%5BX_AYA#*[,"Q&;G:TH@Z\'X9*&AZ2SV?(^\<3PUPMPV18I
M7D14DA<YQR)2E1>L/S6=B1=BF;5B\=+W_U[713,K:%5#RU.B#[#HS7HAF$>,
M4E27I:Y=@'6DZZU/)_-3;RSN/3RE(*.,H#<?:4?E87@K5CE=#9E"<<8Y-CK:
MJU6=%2!#=&-)^'!<I??0L&V^8PL&;H,/O8Y'#-60D:. H:T BUE^D)/\)2YS
M?5!-OX30= 2C5"X*^(;HB/W%6@A>3O<Z.+B]_"@]Q19RQWZY?<1E@?=C0@D?
MS O#@T2$JOZ>Y"48]HIYO(I4=M='PA-P&28Y_&(>S>SN?>NGC^$0(6(X2(C0
MB/_R.9%PE%T@L<NG\#<EF\(AU#@LCEKMARWS'"K-L 5 .,W/S9#"O%__U)^Q
M?_SCUZ]_2GY''QNSZ3"WB]P)WV;=H'A3N;YNQ.,>!,D@\F^2YR4GOZR%)  4
MGS0=>D2,S1P.-Z0QY!:C CQ4#!FEJ '@GA02>8(CN43O#S6HW-BF%__-N"A2
MO;<_2+K.&8$<.-X#EEINL)&XWG[<8# 2I 0AIRW[+/31^#/C$9@;8!WBL(M2
M]E9#1&39Z@L:C74Y3W6!U81Z#:9%/5TO,0"%L0%&7+@P*H@_^"J9M>Q=PR8O
M\@S/RPD"!32#B9?(6WC>;?X(CRRK*$.)TY-+U37 2+O[H?-*-!P[).L:07.X
M911A)'><PUV$8P5)5^A#+2#&"DM\@[W"\S78",TYK[4=OG'S)YMN"LF:^9'T
MS#_ACXU(VS49Z%LN5<KX=WR11 ,QKN)LYYE;V?&H*A<R%#L]/X7)IC,_-)**
MQGMG]HNSO)G6Q40R7/S8,#[[+<8K^21O=2[N1M#!6$C.#=U%%'4LS(<_8P"1
M,5)K5I UGBK&7C4%>Y_CT4L7P/&/N)J3REK3R82K2H1!<9#<GC30K.Y#%0?)
MK4D#K@VX)7$@@-IAK;*G3$AN5B0@7O-*,N'W*CRYX;'LJM&N):&JSB4+M]U=
M5MI7>N/@PV@),4.(M15%;4&O>P^:;A..?)NU>S?"<4K"\37:977R"T:K_Y+S
M&B)D7__T!XX:3W>V#6";RN1[[:,N^#9$2=GH"-4G.GLZ+,/%Z'@8QHUR7_B[
MHO8A'SF4A[05!,D1Z&PJ<FE->)=LW9Y7-8*24W+3JPN,,M8"/M=H,)KW(I/U
M.2G)*7J,>8I["$<L' 9\(Z%D#8ECE>JZ!)WB:[X"F"O,9P]T*QU,O*1MT:Y;
MBJ-I#J_BS!F:[A7HKD)EZ#SXS&2]L?') \8PTF4.1A@GFN"QVW<K.3"[E44/
MLTN+(GB1H:P[* Y9;##V&<?):[;]I&H0U+S//<GB[6GOW%K%98IA@<67>,@6
MX7/UHB.O$9Z "WIP?'2(6%T-C4<ULK74ISU]-ES(!Q\Z*'23*6/FBBJ& -\I
MNYJ4ZJHK.(I)7648H*@NM>!$CI KJP\.;>.E@U'P!841R:CH#>\\3E[A6^E"
M;3_&B7BHS34\5*]L:A93H)L.\-.BE\CA7,'3P#+PR4,G8IZ:2L"X2.Q0JE0&
M !N=BC+VC$ ]X8WSZI*#4QS&GE5YHY=Q#J+)E*);P\1[P]NK.UPUSA:_&QD1
M&+<#(AO3G&<Y;[6\&'',_=IK.F6)!X^FD+H']S@HR<SG>M)]=CK=X3XD=^@]
M(##O@;@/=QU,0 U_)?<AW_<FP[<'@T6WYX1<(22!%MTUG)#K3ON^7)1NU ))
M"L NXO1;)V)QGS;YC&SR5\L<'WJ6_%I7EW .7.@9HQ6_J-L3Q0^WEV=Z$6?Y
M*PB.,E? (%OD7%O.B?72("3U3.7E&4A3D-\@TJ?M8A-CL32MYPQJ.K$H5!@9
M++%_$4<[:U9W?N #)MG*LT<PQD=_H9!JI,;5,5*\"*Q..GNL .P]K"*G]3GN
M1:]M<ACX[K10&KJUZ^2T,5WNQMNQN>[N&>^NJ!:'<PFL_X[9-& O';C'Z^$9
MC\+3XXAX/G_)^46[%CYYT>/<>#:)"B$?E;.S(M^ SNNJ0OL!E0[G4C%+.[Q]
MG"6-+$W9QM0;E-\\_7G0HKQ_ 9"3 -ASBV"NU[\7R6^BT<7)MRDMYSFITYPM
MJC)W5__.[FYXA!KCW(&W<^=O=_8I*ALQG7HTY\$G63SZ/!Y@.EZN8!HKD-3T
M%B^4+#IPPC&$(;B>_^?US\ZG]38\&&I< (WOYO/\[-GI5@_)O,0, BQ:L%X+
M)D[3NV5\A?@USX^.R6<[3!/\[Q/Y[U/Y[[>'Y(S!O[[;0KPB4WM]^MJRE 6X
M)/%_ O?"!=S$*IOO*ZEI3)OAW;#B&BMW8!LF"S2>01M>N/ >[@0^"8>]UWB3
M>+B[!0\]U_NR<NW&(Z-%89!X!Z/H5[=0@B\I#NW.;TB78 MEARNLHXB:]Y_G
M4=$=R92_1!OL(>!N?O1\/,,AW-T K(9DR,Y=CT CW.#N#6OE 0&Q+4+YI>+K
M%BV&.5D,6S@O8FC'AT$O83QR1JNK?_4D,!WHQF./$HEP(2$GUG;/9$^$"'CR
M(#>FX"?B2QB5E!%3%'*&$JN&B=P&"N*[TP'UH!CF-L)$DJ_MO>D!=C(_<*J=
M8?&6ZI<<JK4'OP6G%^Y6WUQ/3+ G\]GF*S'Q:!@3RZP>^6\Z?AP.R6 HM.6B
M@:U/86S]T*,<GL:E1N@WFSVBEV9ZL;[L"V[:W$M_O.N*.?+Q:&>4*\KST8=<
M*1@>E"N'P3IQK#"^UU\IZ?;"KSM!L9362#=T[SCB>'2E0&(TFJMM<X^=XU)H
M=XQJ&(_^!\4E;P+50(CG!PURVB'&KG</,-"H9;SW'&E\X/BH,X8 6-*NEYI"
M\\;"/@1U6_>R(T)@*Q@LLRU=HQ76<M^&"4#ED&]#=<HI[E,TEMQ,38W2%_GX
MR=\0+C/.M7B9=9<9%'>7X*R31^GGV52.JW-V8SM>U7MN>+3HV;:=3U47T?Y_
M]N[?FG(:C^YQIQ^ F#DG,?.+*U=RQ\0(&5_,9!;D(.1T5KL<)I@W*NT/(P/;
MP['PS'WF^=T*+(N.^.U8ONY-D9QJS&-8;(FVA=-8U(L-7S>_JE1%6/@F *[^
M+C ^4<3/T-LWO!?PV/6"AT=E3JN\-H42=#1I8(UROX#Q>)[,%]6E*QYAT$'C
M40<G?,][-YW8HLBQ<BR'/;G1,W"@A#9J.LU7,.#QR!2*K<!AFQ8KY,"4J..O
MIZ=O->I8*'2, J"TZ[*>C!G)5,OGOFG/E]C%#:" F(A,K,1JW0:G8UHQI*+5
MXK?\$^YL7#"_+K.U1J[QCBU[CY$2K: ",8QE)37WVAU9V^19_0BL3)=$M.1(
M#%\)M,04DU+PWWE5M2R>D+ -2SK;UCOZ]N:O#6UV'.Q@QWL%<HNK685ZJK&R
M[;JJ.9(3Z:# DOA Z#)L<8A]B3['J/VNV$?<P RN(YQ-8*LN+BQZV B-.D=H
MD_>2 ](WK?'B9=MB;$0^ 4++2CW3)_1G4(;@)!*5>T8*L'^IO #N47NWN9#C
MT=:5[!//?:BP6])S].BF62]7K(7(%%IL7-VN6]JA9:7N+9+MD<@("HD<G,:
MU^;&3M_]IY4+LL!^SYI9]D]2_1PL<.:7/^M%8\6E R:Y)-=N\P9.A<BMK6F[
MXZ=X<L-?V52>/0<NL>0[^A&+".X/H_"&8K_'U#=@R-A',+]'BO+R^$-F$UF,
M."@)R2*>/FA1DH0IAXQ=^G!1?,R91\GQ7DI'(8*(4)F_!%YHM<PA,^K 3=0G
M54+R;P8A-NY!P9=(NNE\L$C\7"G%>$Z84IWF) AQAD@-,P^20)&+#4^0PU/8
M>F-ZMYE0T^GE0F7F-,@P.5@T0\E3$ HUJB>=&W%=92*6>1 /P*7YFR]4Y5 4
MR>D,K!>P4%[0'O'->E\(]7D0V5U6#<:6IZ2$^RS@A^'0I!X&0CK')70%U;01
MN]^P;""QN[3<.H@2U9C=8:3.W'3I"D\Z1BX=>2%^CIMWL9S'E*BIK@Y";;:5
M5V&:K)SA9_%)\@P6]I=TFOA>Y9_DF*&H:FFM$2, ]Q;.=VE?HWUS;FQ]#Y%2
M!R3E(VJ6,<LG=*D7%:9K_6_F0559JA0:2ET;,]=J.?;' FU42>*EQ-D&IO>,
M22N$*BEETAIM(!/7=L@>+S).X07;Z\;A]$ FQY_/A!]G?I$OJM52"#&JQ458
M<H$K/?0,@FGB<SCQ)').N;FX7V".K),-%N&4L,H\JZ[3F_*HSZO%S-!=T8ZG
MUK\UOBW1]%>BVZ(+R<J .%B(+O,D*D.($1#DD+&_PJ%VP[U $_0-2B[/"9).
MR2G\JMPML*T83@NV:LV70]=!RG^*QJ]C%+./ARL6X[JN1?Q[(A ,8DT6PEF2
M"L83?XLR'W9 3OK5WG>BZ)9M:]2 =T71588^P.UI>)SP#I5PCK?%\;-=>>I\
M#?E+0JM"NG)>8"E7_FF%V3"<^GR!.0-'HS'-%MF2CHOL4"(;I$[K!&4'W'B4
M<73ZZ;$TE6PBEW1=3U@$TH^K-7-7D3KFPY!*THJ4^Q0!UG*=<=MI'[)Z4J#P
M8;*?,WQYB2>'L92&&T>00VW@1A-VG?SHK#$PIAF+JUTU%M>V?+]$3V[%!OE(
M-L@?V%ZW^)=W&7_%@_M>U*$/L'9PR4A;AG*&OJ[A_@:[D!:SQ<9K1O$!SO"Q
M3LMZJW2177HFMU;,'&W]2KQZQ(_F48]8*V,(6>6UG3?H<35>I"5XHDPD17B$
M>PD$^WFQ(A6:2Z1(%,1&BX.0JGX]9:4:B!%Q5"1G)T.=FHYMN&CH]JRJ2R$D
M=?<K#.NCKX_F-F@:&IC747P[*C<(J\OL9$@R,=#67=U+LK\HH)L5B[7C&&XJ
MLZXD+:-%),O_(E<4QZ5H%C_XRVJ]D"HDC/R"4;&FH"H_C%QMY5).^5%95U^K
M>U,^% 6-TK'4V")Y_B!VQZ/8PI& ME-XC3G6'XR*=CG1GMX\\"O!#78\@5>T
M+$$#7'VU*WZ3\T+\<]4B#:HJ<$/XIU24@&NCC(&1IH(E5!."M13!6S<=&.9X
MA#7PZPD8@$56XUFT\QBL*[[_L,6"))SK&$6S[9=HF:TX&8^FP5<Z?/PW&UOT
M"W@NR55A,0T&X?IQ2NL/Z[.8ML6!$Q4=:Q]Z(Y&*0Q%I'2&%9PJFT^ 64GL+
M1R7^:F?XNZS*1W#"4*Z!X%6PJ#Z-[343)-H#JKJJ\T<YANPNW.,0O%' SF=@
MN&"F4\PYFJ7S,VFFEUG!]?A) VO9< :)92/,//32\%,>:Q)PH[G:W!OSD-DQ
MYC4)=E0FY!.83#F**0\LC6OE%E]GV?C1A^ >.6<8!8!XN%1L1=HL5?1_[0$,
M%RB.F=^46;1SB2EE0FC(DF;P/#I!H]XR.C:-<U-B+U5I-5/"$1?*Y^C;UG@V
M<]%6-*,SGV175]: E=@AMO$$>M66BY-Z)*-=@WCZC1=_,GZ.9]%ZITG/:I_T
M!#ZB.RMYRRWUW.*R\!F6;@V,$.H4/P^A-?]'QJ27)-PY],-DS5*)]%>79!6A
M>R869)M0!0_0!"\%?J*X,!NH\.%'$^(0QN!C7C:\E!SMB?8N[.]-O^*WO<5/
MNVZH&%TG4]4.)6$:?K9WV4BC9+NKT_.1)CLU*0(0)J4@E/WLR1,_P%E@_#7.
M4H0W7,FD"\I>4&["&X67FXV] :N&;LAU?$B>"\9+>,U<B"[CY1N/9/TN,_$<
MC&8#(1OQM7?K5-T#F:/9;@D^$OUTO'3$K\M6M <VFPW_E1Z#H%@]4X@%1&R0
M,_==(#91[]U(^SAQ154O6.7%.FA29?4,1\DF7E6#D1:?/F+SI27PW"XSZWS\
MBT\QY9AS%1J'+H/LLK7&MNX,Q$_'MTJYH$1C4)M)!6^-2<!A$-4$KC@2X7(
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ME@&8'OO&[\Z^X2IR@^S> 2JU5NQ^=56?D-9QER4Q+Q8;>Q? E5GU%N5.P=L
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M4T%R+@R43,4945N3DV+=Z@DD!K,5'$2*#DI[(-TF6ZP!]=SUGS$<_5HQ^@
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M/I,SCXOBVR!1+T&B=.LM>*W84AI:K&='1\<'V>'!\3-:,YJKSL9"@UD^4S8
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M=.@!7/#52GT*4)GS1>%<Z?>.24_)ON!35_,ODAWN!;$BWZ9_4=@L,D.WF?A
MG,,6_3K74\MS!VX[^Z2_D:K>'[K4Q%KZU2 9)K081-JF N:4L0 O%#$_]T]_
MZ?J3Z:\_8+1J#>I"8R:_G+[0VR/SZ?DF9;\EJK]SB*S3) /JZ[L)JTHA6OT
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M5:"MYDK@J,7PQ!4D:,*F6'AK>*C%<$_9F^I^C#)13&^@>:XC;^ Z!ZQ")-;
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M53*5<"-LX181+$JC=(1;BB/#IJ[$6SD+BL% D_D6DJD'H#(G$ICP)^<%[>6
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MAP8<63)[+GW4-NB43)2VG.S'P)L9B"[5F%9KUE3[D',K3G-EKI#IM!3B#N(
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M?&1+1+CG-SGNZ<.?(K%_W:07!3=!ER W:CY-R0_OI9<IO<3D]]B,+-/B*K/
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M@'V))C'S&WA(DST"0P5\2P9LM-=Q4=QQJ;?,GUC)=O'T#XWH/?\!4$L#!!0
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M9'DJK"/B]A([8MAB<V>39<(IB8DB;/&H+\:"&&NG,:M3MA=8G5M+RYT=DY$
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M,3$N:'1M4$L! A0#%     @ !T!26F2A>W>N"0  0B   !
M ( !UKH  &0Y,3<U.3ED97@U,2YH=&U02P$"% ,4    "  '0%):2=U$W3L#
M  !$"P  $0              @ &RQ   ;G!C92TR,#(U,#(Q-"YX<V102P$"
M% ,4    "  '0%):X=8QC9 &  "J1@  %0              @ $<R   ;G!C
M92TR,#(U,#(Q-%]L86(N>&UL4$L! A0#%     @ !T!26BI27L+2!   -RP
M !4              ( !W\X  &YP8V4M,C R-3 R,31?<')E+GAM;%!+!08
1    !@ & 'T!  #DTP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d917599d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="npce-20250214.xsd" xlink:type="simple"/>
    <context id="duration_2025-02-14_to_2025-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2025-02-14_to_2025-02-14"
      id="Hidden_dei_EntityRegistrantName">NeuroPace Inc</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-293">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-02-14_to_2025-02-14"
      id="Hidden_dei_EntityCentralIndexKey">0001528287</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-304">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-305">2025-02-14</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-306">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-307">001-40337</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-308">22-3550230</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-309">455 N. Bernardo Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-310">Mountain View</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-311">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-312">94043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-313">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-314">237-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-315">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-316">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-317">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-318">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-319">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-320">NPCE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-321">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-322">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-02-14_to_2025-02-14" id="ixv-323">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
